par Bernaert, Denise 
;Brewer, Linda L.M.;Macmanus, John J.‐.;Galand, Paul
Référence International journal of cancer, 43, 4, page (719-727)
Publication Publié, 1989
;Brewer, Linda L.M.;Macmanus, John J.‐.;Galand, Paul Référence International journal of cancer, 43, 4, page (719-727)
Publication Publié, 1989
Article révisé par les pairs
| Résumé : | Oncomodulin is a calcium‐binding protein, detectable in extra‐embryonic human and rat placental cells and in a wide variety of tumors, but not in any normal embryonic or adult rodent or human tissues. It is also absent from proliferatively active fetal or regenerating adult rat liver. The presence of this oncodevelopmental marker was investigated in preneoplastic and neoplastic liver lesions during hepatocarcinogenesis induced in rats by DENA treatment, using an antibody raised against purified oncomodulin. Positive immunostaining was observed in foci of altered hepatocytes, in neoplastic nodules and in HC, but not in the histologically normal surrounding liver parenchyma. The proportion of oncomodulin‐positive foci gradually rose from 20–25% at 2–3 months after DENA treatment, to about 88% at 6 months and later. The proportion of positive neoplastic nodules increased from 50% at 5 months to about 73% (range 36–100) at 9 months and later; 88% of the HC found 10 to 20 months after DENA treatment were also positive. That early neoplastic nodules are oncomodulin‐positive in a proportion (50%) similar to that of foci after the same duration of treatment is consistent with a lineage relationship between them but makes it unlikely that oncomodulin expression conditions the focusnodule transition. The role, if any, of oncomodulin in malignant progression remains to be elucidated. It seems out of the question that it is a simple correlate of proliferative activity. Copyright © 1989 Wiley‐Liss, Inc., A Wiley Company |
